VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
HOLX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HOLXHologic, Inc.
$76.01$17.0B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

HOLX logoHologic, Inc.(HOLX)Earnings, Financials & Key Ratios

HOLX•NASDAQ
$76.01
30.5× P/E·Price updated Jun 20, 2026
SectorHealthcareIndustryMedical InstrumentsSub-IndustryDiagnostics and life science tools
AboutHologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.Show more
  • Revenue$4.1B+1.7%
  • EBITDA$1.01B-14.9%
  • Net Income$566M-28.3%
  • EPS (Diluted)2.49-25.0%
  • Gross Margin60.99%+10.3%
  • EBITDA Margin24.73%-16.4%
  • Operating Margin17.42%-20.5%
  • Net Margin13.8%-29.6%
  • ROE11.12%-28.6%

HOLX Price & Volume

Hologic, Inc. (HOLX) stock price & volume — 10-year historical chart

Loading chart...

Stagnant Revenue Growth Masks Underlying Margin Volatility

Investment Thesis • Updated 2026Q1

VerdictNeutral
Growth:Mixed
Profitability:Moderate
Financial:Healthy
Cash Flow:Stable
Primary Risk:Post-pandemic revenue normalization

Key Thesis Takeaways

  • Hologic faces a challenging post-pandemic transition characterized by muted 2.5% year-over-year revenue growth in 2026Q1 and significant earnings volatility.
  • While the company maintains a healthy balance sheet with a 0.48 debt-to-equity ratio, its reliance on the Panther platform for recurring revenue remains a key risk factor.
  • Investors should monitor whether the company can stabilize its operating margins, which currently sit at 22.6%, while balancing aggressive share repurchases against the need for organic innovation.

Verdict Logic

while the company maintains a solid liquidity buffer with $2.2 billion in cash, the stagnant top-line growth and inconsistent earnings quality suggest a cautious approach until the company demonstrates a more sustainable path to margin expansion beyond the current 22.6% operating margin.

HOLX Growth Metrics

Hologic, Inc. (HOLX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years4.25%
5 Years1.66%
3 Years-5.53%
TTM2.16%

Profit CAGR

10 Years15.7%
5 Years-12.69%
3 Years-24.26%
TTM-26.9%

EPS CAGR

10 Years18.66%
5 Years-9.97%
3 Years-21.41%
TTM-24.29%

Return on Capital

10 Years13.35%
5 Years17.13%
3 Years9.39%
Last Year8.84%

HOLX Recent Earnings

Hologic, Inc. (HOLX) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 9/12 qtrs (75%)
Q1 2026Latest
Jan 29, 2026
Metric
Actual
Est
EPS
$1.04-4.6%
$1.09
Rev
$1.0B-2.2%
$1.1B
Q4 2025
Nov 3, 2025
Metric
Actual
Est
EPS
$1.13+2.7%
$1.10
Rev
$1.0B+1.5%
$1.0B
Q3 2025
Jul 30, 2025
Metric
Actual
Est
EPS
$1.08+2.9%
$1.05
Rev
$1.0B-1.0%
$1.0B
Q2 2025
May 1, 2025
Metric
Actual
Est
EPS
$1.03+1.0%
$1.02
Rev
$1.0B+0.5%
$1.0B
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q1 2026LatestJan 29, 2026
$1.04vs $1.09-4.6%
$1.0Bvs $1.1B-2.2%
Q4 2025Nov 3, 2025
$1.13vs $1.10+2.7%
$1.0Bvs $1.0B+1.5%
Q3 2025Jul 30, 2025
$1.08vs $1.05+2.9%
$1.0Bvs $1.0B-1.0%
Q2 2025May 1, 2025
$1.03vs $1.02+1.0%
$1.0Bvs $1.0B+0.5%
Based on last 12 quarters of dataView full earnings history →

Latest HOLX News

Recent stock market news and headlines for Hologic, Inc. (HOLX)

Business Wire·Jun 17, 2026
Hologic's New Sustainability Report Marks 40 Years of Impact

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc., a global leader in women's health, today released its 2025 Sustainability Report. The new report coincides with Hologic's 40th anniversary and underscores how the company's longstanding purpose — to enable healthier lives for women everywhere, every day — continues to drive progress for patients, communities and the planet. “We have always firmly believed that our success as a company is fundamentally tied to our ability and commitment to help.

Business Wire·Jun 16, 2026
Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. today announced a significant and far-reaching victory in the Unified Patent Court (UPC) in Germany, which ruled that Siemens* infringed upon a critical Hologic mammography technology patent in Siemens' latest mammography system. The court imposed a sweeping injunction, immediately prohibiting Siemens from making, offering, placing on the market, using or importing or storing for those purposes its MAMMOMAT B.brilliant systems across Germany, F.

Peers Comparison

Key metrics vs top competitors for Hologic, Inc. (HOLX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
HOLX logoHOLXHologic, Inc.Current
$76.01$16.97B30.531.74%13.8%11.12%—
BDX logoBDXBecton, Dickinson and Company
$156.30$56.63B26.818.23%5.33%4.54%—
BAX logoBAXBaxter International Inc.
$22.86$11.8B-13.065.72%-9.7%-16.5%—
IDXX logoIDXXIDEXX Laboratories, Inc.
$570.25$45.29B43.6010.42%24.63%70.87%—
DXCM logoDXCMDexCom, Inc.
$73.57$28.39B35.2015.6%19.31%33.83%—
ISRG logoISRGIntuitive Surgical, Inc.
$427.30$151.33B54.2920.51%28.15%16.89%—

Compare HOLX vs Peers

Hologic, Inc. (HOLX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs BDX

Most directly comparable listed peer for HOLX.

Scale Benchmark

vs TMO

Larger-name benchmark to compare HOLX against a more recognizable public peer.

Peer Set

Compare Top 5

vs BDX, BAX, IDXX, DXCM

HOLX SEC Filings & Documents

Hologic, Inc. (HOLX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Apr 7, 2026·SEC

Material company update

Apr 6, 2026·SEC

Material company update

Feb 6, 2026·SEC

10-K Annual Reports

2
FY 2025

Nov 18, 2025·SEC

FY 2024

Nov 27, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Jan 29, 2026·SEC

FY 2025

Jul 31, 2025·SEC

FY 2025

May 2, 2025·SEC

Get notified when HOLX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

HOLX Frequently Asked Questions

Hologic, Inc. (HOLX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Hologic, Inc.'s revenue?

Hologic, Inc. (HOLX) reported $4.13B in revenue for fiscal year 2025. This represents a 4578% increase from $88.2M in 1996.

How fast is Hologic, Inc. growing?

Hologic, Inc. (HOLX) grew revenue by 1.7% over the past year. Growth has been modest.

Is HOLX profitable?

Yes, Hologic, Inc. (HOLX) is profitable, generating $543.9M in net income for fiscal year 2025 (13.8% net margin).

Dividend & Returns
What is HOLX's return on equity?

Hologic, Inc. (HOLX) has a return on equity (ROE) of 11.1%. This is reasonable for most industries.

What is Hologic, Inc.'s free cash flow?

Hologic, Inc. (HOLX) generated $999.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in HOLX back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →